title: [Changes in expression level of TLR9 and BD-2 genes in cornea of mice with viral keratitis].
abstract: OBJECTIVE
  Study of innate immunity genes expression (TLR9 and BD-2) in epithelial cells of mice cornea on the model of viral keratitis during the application of immunotherapy.
  
  
  METHODS
  RNA isolation from cornea cells was performed by using RNeasy Mini Kit (Qiagen) and "RIBO-sorb" (ILS, Russia) reagent kits. "Kit for performing PCR-RT in the presence of intercalating dye SYBR Green I" (Syntol, Russia) was used for performing PCR. Data on gene expression is presented in decimal logarithms (relatively to 1 million of beta-actin gene copies).
  
  
  RESULTS
  In C57B1/6 mice line at day 1 post infection the virus was detected in 33% of animals, at 3 days - in 90%, at 7 days the number of infected mice started to decline. In cornea of the mice infected with HSV-1 a significant decrease of TLR9 gene expression was observed. Administration of a complex of natural cytokines and antimicrobial peptides (Superlimf preparation) caused statistically significant increase of expression levels of the studied TLR9 and BD-2 genes.
  
  
  CONCLUSIONS
  The model of viral keratitis and expression analysis of recognizing receptor TLR9 and defensin (BD-2) genes can be used to study mechanism of action of various preparations during infection in eye tissues and evaluation of possibility of their use in complex therapy of ophthalmic herpes.
authors.forename: O A
authors.initials: OA
authors.lastname: Gankovskaia
authors.forename: L V
authors.initials: LV
authors.lastname: Gankovskaia
authors.forename: L V
authors.initials: LV
authors.lastname: Koval'chuk
authors.forename: M V
authors.initials: MV
authors.lastname: Chereshneva
authors.forename: T V
authors.initials: TV
authors.lastname: Gavrilova
authors.forename: V V
authors.initials: VV
authors.lastname: Zverev
mesh_terms: D000199:Actins / Q000235:genetics / Q000378:metabolism; D060433:Administration, Ophthalmic; D000818:Animals; D023181:Antimicrobial Cationic Peptides / Q000008:administration & dosage / Q000276:immunology; D016207:Cytokines / Q000008:administration & dosage / Q000276:immunology; D004195:Disease Models, Animal; D019573:Epithelium, Corneal / Q000187:drug effects / Q000276:immunology* / Q000821:virology; D015870:Gene Expression / Q000187:drug effects* / Q000276:immunology; D018259:Herpesvirus 1, Human / Q000187:drug effects / Q000276:immunology* / Q000472:pathogenicity; D006801:Humans; D016233:Immunotherapy, Active / Q000379:methods*; D016849:Keratitis, Herpetic / Q000188:drug therapy / Q000276:immunology / Q000821:virology; D051379:Mice; D008810:Mice, Inbred C57BL; D009883:Ophthalmic Solutions / Q000008:administration & dosage; D012367:RNA, Viral / Q000032:analysis / Q000096:biosynthesis; D020133:Reverse Transcriptase Polymerase Chain Reaction; D051217:Toll-Like Receptor 9 / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D023083:beta-Defensins / Q000235:genetics / Q000276:immunology* / Q000378:metabolism
chemical_list: D000199:Actins; D023181:Antimicrobial Cationic Peptides; D016207:Cytokines; C117047:Defb2 protein, mouse; D009883:Ophthalmic Solutions; D012367:RNA, Viral; D051217:Toll-Like Receptor 9; D023083:beta-Defensins